Form 4: Rapport Therapeutics CEO Sells $320K in Stock

Rapport Therapeutics CEO Abraham Ceesay executed pre-planned sales of over 10,000 shares of common stock totaling approximately $320,000 through Rule 10b5-1 trading plans.

Summary

• Abraham Ceesay, CEO and Director of Rapport Therapeutics, Inc. (RAPP), sold a total of 10,916 shares of common stock.
• The sales were executed on February 18, 2026, under pre-arranged Rule 10b5-1 trading plans adopted on December 12, 2024.
• Direct sales included 3,552 shares at a weighted average price of $29.0516 and 2,281 shares at $29.7983.
• Indirect sales, through the Dorothy Ceesay Irrevocable Trust, included 2,983 shares at $29.0443 and 2,100 shares at $29.7965.
• Following these transactions, Ceesay directly owns 556,247 shares and indirectly owns 20,729 shares via the Dorothy Ceesay Irrevocable Trust and 81,729 shares via the Ceesay Family Irrevocable Trust.
• The total value of the shares sold is approximately $320,372.65.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative event. While the sales are pre-planned, any insider selling, especially by a CEO, can be perceived as a lack of strong conviction, even if it's for personal liquidity or diversification.

Negatives

• An insider, the CEO, sold a significant number of shares, which could be interpreted negatively by some investors, despite being pre-planned.
• The sales represent a reduction in the CEO's direct and indirect holdings, potentially signaling a lack of increased conviction or a need for liquidity.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, even when pre-planned under Rule 10b5-1, are routinely monitored by investors for insights into management's perspective on future company performance. While these sales are often for personal financial planning, a consistent pattern of insider selling across multiple executives or significant sales relative to total holdings can sometimes signal a cautious outlook, though this single filing does not provide enough context for such a broad conclusion.

Related Party Transactions

• Sales of 5,083 shares were conducted indirectly through The Dorothy Ceesay Irrevocable Trust.
• Abraham Ceesay disclaims beneficial ownership of shares held by The Dorothy Ceesay Irrevocable Trust and The Ceesay Family Irrevocable Trust, except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: May interpret the CEO's sales, even if pre-planned, as a signal regarding the company's near-term prospects, potentially leading to minor negative sentiment or increased scrutiny.

Key Dates

Recommendation

The insider sales by CEO Abraham Ceesay, while notable, were executed under a pre-arranged Rule 10b5-1 trading plan. This suggests the sales are for personal financial planning rather than a reaction to new, adverse company developments. Without additional context on the company's fundamentals or other market factors, these routine, pre-scheduled sales do not warrant a change from a 'hold' position. Investors should monitor future filings and company performance for more substantive indicators.

Keywords

Rapport Therapeutics, RAPP, Abraham Ceesay, Insider Trading, Form 4, Stock Sale, CEO, Rule 10b5-1, Beneficial Ownership, Biotechnology